Form 4: Vertex Pharmaceuticals EVP Charles Wagner Jr. Reports Acquisition of Performance Shares
SEC Form 4 Filing
Charles Wagner Jr., EVP & Chief Financial Officer of Vertex Pharmaceuticals, reports the acquisition of performance shares related to performance stock unit awards.
Summary
- Charles F. Wagner Jr., EVP & Chief Financial Officer of Vertex Pharmaceuticals, filed a Form 4 indicating changes in beneficial ownership.
- On February 4, 2025, Wagner acquired 10,262 shares of common stock related to a performance stock unit award granted on February 1, 2022, and 7,114 shares of common stock related to a performance stock unit award granted on February 7, 2024.
- The performance goals for these awards were certified by the issuer's management development and compensation committee on February 4, 2025.
- Following these transactions, Wagner directly owns 61,528 shares of Vertex Pharmaceuticals common stock.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine filing related to executive compensation and the vesting of performance shares, indicating that performance goals were met.
Positives
- The acquisition of performance shares indicates that performance goals were met, which could be viewed positively.
Future Outlook
The document does not contain any specific forward-looking statements or guidance.
Industry Context
Form 4 filings are a routine part of executive compensation and provide transparency into the holdings of company insiders. The vesting of performance shares suggests that the company has met certain performance targets.
Stakeholder Impact
- Shareholders may view the vesting of performance shares positively, as it suggests the company is meeting its performance goals.
Key Dates
| Date | Description |
|---|---|
| 02/01/2022 | Date of grant for the first performance stock unit award. |
| 02/07/2024 | Date of grant for the second performance stock unit award. |
| 02/04/2025 | Date of transaction and certification of performance-goal attainment. |
| 02/06/2025 | Date of Form 4 filing. |
| 02/17/2025 | Installments begin for the vesting of the 2024 performance stock unit award. |
| 02/26/2025 | Vesting date for the 2022 performance stock unit award. |
Keywords
Form 4, beneficial ownership, performance shares, stock options, VRTX, Vertex Pharmaceuticals, Wagner, executive compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.